Niraparib Maintenance in Patients With Advanced Ovarian Cancer at Neoadjuvant Setting

Summary

This study aims to evaluate the effects of niraparib in those who have received neoadjuvant chemotherapy and subsequent interval debulking surgery, with or without hyperthermic intraperitoneal chemotherapy, and would also explore if there are any biomarkers, other than BRCA / HRD status and platinum sensitivity, that may help to identify those who may benefit from PARPi especially those who are HRD negative.

Timeline

Start

2020-05-01

Primary completion

2023-10-01

Completion

2023-10-01

Drugs

Indications